Here is the design of a clinical trial:

Official Title: A Double-blind Randomised Placebo-controlled Feasibility Study to Assess the Impact of Octreotide Infusion During Liver Transplantation on Post-operative Renal Failure.

Included conditions:
- Liver Transplantation
- Renal Failure

Study Armgroups:
- {'label': 'Intervention group', 'type': 'ACTIVE_COMPARATOR', 'description': 'Octreotide intravenous infusion, 100mcg bolus with a subsequent infusion of 100mcg per hour during surgery.', 'interventionNames': ['Drug: Octreotide Acetate']}
- {'label': 'Placebo group', 'type': 'PLACEBO_COMPARATOR', 'description': 'Sodium chloride 0.9% w/v', 'interventionNames': ['Other: Placebo']}

Interventions:
- {'type': 'DRUG', 'name': 'Octreotide Acetate', 'description': 'Octreotide syringes will contain 50ml of octreotide acetate at 20mcg/ml in 0.9% w/v sodium chloride in water.', 'armGroupLabels': ['Intervention group']}
- {'type': 'OTHER', 'name': 'Placebo', 'description': 'Sodium chloride 0.9% w/v', 'armGroupLabels': ['Placebo group']}

Primary Outcomes:
- {'measure': 'Ability to recruit patients.', 'description': 'This will be assessed by:\n\n• Ability to recruit patients (target: ≥ 30% consent rate of eligible patients admitted for transplant)', 'timeFrame': 'Approximately 180 days.'}
- {'measure': 'Completion of the study intervention.', 'description': 'This will be assessed by:\n\n• The percentage of patients successfully completing the study intervention. Defined as eligible patients who receive the entire study drug infusion in a blinded manner.', 'timeFrame': 'Approximately 9.5 hours.'}

Please estimate the sample size based on the assumption: 
The sample size will allow estimation of patient consent rate with a 95% CI of ± 10% based on 100 participants approached. Survival to discharge is above 96% for both study sites, indicating that ninety-day follow-up data collection will be achieved for the majority of patients.
Sample size
        Thirty patients will be recruited from two sites, with 20 in the study drug (octreotide) arm and 10 in the placebo. This sample will allow us to demonstrate the feasibility of conducting a full-scale randomised trial. This study is not powered to detect differences in treatment effect but will obtain estimates of an effect and its variance.30 This sample size will allow us to estimate patient consent rate with a 95% CI of Â± 10% (based on 100 participants approached). The secondary outcome data will provide the required information for a sample size calculation for the primary end point of a subsequent trial.31 Survival to discharge is above 96% for both study sites and hence it is likely that the ninety day follow data collection will be achieved for the majority of patients.
        
          Recruitment rate
          Over 275 patients per year will be eligible for study inclusion across the two study sites. With a 10 month recruitment period, this requires a 13% recruitment rate. A recent interventional trial in liver transplantation at the RFH achieved a 53% recruitment rate.32 Staff involvement and recruitment strategies will be similar in this study indicating this is a deliverable recruitment target.